1. Laboratory
  2. Laboratory medicine
  3. Inflammatory disease test kit
  4. Siemens Healthineers - Laboratory Diagnostics

Inflammatory disease assay kit N Latex aTNFα
clinicalserumplasma

Inflammatory disease assay kit - N Latex aTNFα - Siemens Healthineers - Laboratory Diagnostics - clinical / serum / plasma
Inflammatory disease assay kit - N Latex aTNFα - Siemens Healthineers - Laboratory Diagnostics - clinical / serum / plasma
Add to favorites
Compare this product
 

Characteristics

Applications
for inflammatory diseases
Sample type
clinical, serum, plasma
Analysis mode
automated
Result display time

7 min, 9 min

Description

Monitor the effectiveness of TNF alpha inhibitors adalimumab, infliximab, and etanercept with one automated, cost-effective, and easily accessible assay The N Latex aTNFα assay1 for use on Atellica® NEPH 630,1 BN™ II, and BN ProSpec® Systems is designed to quantify adalimumab, infliximab, and etanercept in human serum. It is an automated, cost-effective assay that enables physicians to make decisions on optimizing the effectiveness of therapeutic anti-inflammatory medication regimens. Features & Benefits Flexible assay. Few steps. Fast results. The N Latex aTNFα assay1 from Siemens Healthineers provides: Consolidated, random-access testing and streamlined workflow One assay for quantification of three TNF-alpha inhibitors using individual calibrations Fully automated testing for improved workflow Individual or parallel determination of adalimumab, infliximab, and etanercept from different samples by providing separate assay protocols for each application No need to pool samples Economical testing and cost efficiency Broad initial measuring range covering the therapeutic range of each substance that helps reduce the need for redilutions and supports economical reagent use Separate calibrators and controls that enable cost-effective use of assay components Ability to measure just one sample without wasting additional testing capacities Improved patient management and clinical outcomes Insight into response to and effectiveness of anti-inflammatory medication containing adalimumab, infliximab, and etanercept Optimization of individual therapeutic dosage regimens for improved personalized patient management and therapy

Catalogs

*Prices are pre-tax. They exclude delivery charges and customs duties and do not include additional charges for installation or activation options. Prices are indicative only and may vary by country, with changes to the cost of raw materials and exchange rates.